PLUR

Pluri (PLUR)

About Pluri (PLUR)

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Details

Daily high
$3.02
Daily low
$2.96
Price at open
$3.00
52 Week High
$7.13
52 Week Low
$2.88
Market cap
28.1M
Dividend yield
0.00%
Volume
6,006
Avg. volume
43,697
P/E ratio
-.99

Pluri News

Details

Daily high
$3.02
Daily low
$2.96
Price at open
$3.00
52 Week High
$7.13
52 Week Low
$2.88
Market cap
28.1M
Dividend yield
0.00%
Volume
6,006
Avg. volume
43,697
P/E ratio
-.99